Language

English

Publication Date

9-15-2023

Journal

STAR Protocols

DOI

10.1016/j.xpro.2023.102386

PMID

37379217

PMCID

PMC10331592

PubMedCentral® Posted Date

6-27-2023

PubMedCentral® Full Text Version

Post-print

Abstract

Dysbiosis of the gut microbiome is implicated in the growing burden of non-communicable chronic diseases, including neurodevelopmental disorders, and both preclinical and clinical studies highlight the potential for precision probiotic therapies in their prevention and treatment. Here, we present an optimized protocol for the preparation and administration of Limosilactobacillus reuteri MM4-1A (ATCC-PTA-6475) to adolescent mice. We also describe steps for performing downstream analysis of metataxonomic sequencing data with careful assessment of sex-specific effects on microbiome composition and structure.

For complete details on the use and execution of this protocol, please refer to Di Gesù et al.1

Keywords

Male, Female, Animals, Mice, Gastrointestinal Microbiome, Microbiota, Limosilactobacillus reuteri, Probiotics

Published Open-Access

yes

fx1.jpg (282 kB)
Graphical Abstract

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.